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Introduction 
It is well recognised that it can be difficult for researchers to ensure that proper 
consent provisions are in place for their research project. If this can be difficult for 
those conducting a single site study, those difficulties can be compounded when that 
study becomes a member of an international scientific research consortium. These 
consortia bring together often diverse groups of researchers who, while working on a 
common topic, may represent different countries, cultures and scientific 
methodologies. Harmonising consent information and processes across these studies 
can be a complicated task. At the local level, participants need to be informed of the 
details of the study to which they are being recruited, and informed of the implications 
of the study’s inclusion in the consortium. Likewise, the international consortium 
needs to make certain that member studies have met appropriate consent requirements 
so that participants’ samples and data can be shared with and used by the consortium 
for agreed purposes. A considerable amount of time and effort is needed to ensure an 
international consortium is running consistently across its constituent parts. And as 
the consortium grows, so do the complexities of dealing with the different regulatory 
and cultural norms of its members, while staying within the organisational 
requirements of the consortium itself. But a level of consistency, in terms of consent 
to use of data and samples, must be achieved across the consortium members in order 
for its work to proceed while respecting the consent provisions agreed to by 
participants. The question of how to arrive at this benchmark is a vital one. This paper 
will present issues raised as a result of an examination of consent materials used by 
International Cancer Genome Consortium (ICGC) members. 
The rise of international consortia 
The number of international consortia creating resources for the scientific community 
is increasing, yet they differ in how data and samples are collected, stored and 
disseminated. The International HapMap Project and the 1000 Genomes Project, for 
example, created open and public resources of anonymous genotype data.2 Others 
collect identifying data and samples. The Type 1 Diabetes Genetics Consortium 
(T1DGC),3 a project identifying genes related to this disease, used a centralised 
system where samples and personal data were collected, coded and stored in regional 
network repositories as well as in a central repository in the United States. T1DCG 
member projects had to comply with applicable US national regulatory requirements.4 
The Malaria Genomic Epidemiology Network (MalariaGEN) is a global research 
network that was established to investigate genomic variation in humans on the 
biology and pathology of malaria and has partner institutions in 17 countries.5 In this 
latter network, after coding data and samples to protect the confidentiality of 
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participants, researchers “…contribute [them] to a central repository of DNA samples 
and a central database of core phenotypic data for each Consortial Project.”6 
 
In 2008,7 the ICGC “...was launched to coordinate large-scale cancer genome studies 
in tumours from 50 different cancer types and/or subtypes which are of clinical and 
societal importance across the globe.”8 Founders agreed that no one country could 
conduct the project on its own but that multiple initiatives would unnecessarily 
duplicate efforts. Acting in a concerted fashion gives ICGC researchers opportunities 
to harmonise data sets, leading to accelerated dissemination of data and analytical 
methods to the user community.9 As of December 2011, 39 projects in 13 
jurisdictions are active under the ICGC banner.10 These include both prospective 
studies and retrospective uses of existing samples and datasets. The ICGC is 
continuing to bring in new members and member studies are publishing the results of 
their work within the ICGC.11 
 
Datasets from ICGC member projects are also now accessible. Unlike T1DGC and 
MalariaGen, the ICGC chose a federated system where samples would be kept by the 
local project and data derived from samples and other associated data would be 
submitted and made available through open and controlled access databases. Open 
access data is publically available data from the member projects which can be 
searched via the ICGC Data Portal to find, for example, mutations on chromosome 7 
found in participants with malignant melanoma. Participant data is coded and even if 
the elements in this database (i.e., gender, cancer pathology) were aggregated, they 
would not create a dataset that is unique to, and thus could identify, an individual. On 
the other hand, Controlled Access Datasets contain “…composite genomic and 
clinical data that are associated to a unique, but not directly identified, person.”12 
International researchers need to apply to and be approved by the ICGC Data Access 
Compliance Office (DACO) in order to be given access to controlled data. 
 
International consortia such as ICGC are virtual in nature and although ‘management’ 
offices are located in one country, the consortium itself is not bound by the legislation 
of any one country. In the case of ICGC, the Secretariat is hosted by the Ontario 
Institute of Cancer Research in Toronto, Canada. Decisions on how the consortium 
will work, however, are made by the ICGC Executive Committee, which comprises 
representatives from funding agencies based in the countries of participating projects. 
This bottom-up approach grounds decisions at the level of the member projects, but 
does not base them on any one set of national laws. Decisions are negotiated between 
the members, who use international instruments,13 in addition to applicable national 
ones,14 as guidance when creating policies and seeking best practices. However, not 
having a single national regulatory structure in place can potentially leave gaps in 
oversight. If no top-down compliance mechanism exists, an international consortium 
has to trust that its member studies are being conducted in accordance with local 
regulations, national and international law and ethics policies, and have appropriate 
institutional oversight. In addition to that collegial trust, the international consortium 
itself needs to have policies and guidelines in place, with appropriate governance 
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systems, for its oversight and to assist it in seeking the harmonisation of working 
practices that will enable it to proceed. 
 
But these working practices always need to take into account that member studies 
represent different countries and cultures.15 Consent form language and the consent 
process itself will also vary from project to project and is necessarily culture- and 
context-dependent.16 Member studies may also use varying scientific methodologies; 
regulatory and ethical review procedures for seeking consent for a prospective 
research study will differ from those for use of existing samples consented for 
different research purposes. But even accepting these differences, the area of informed 
consent is one vital area in which there must be consensus, or at a minimum, 
interoperability between compatible approaches and core elements, in order that 
participants are informed about the research in which they have agreed to participate.  
 
Recent reports have highlighted how unclear consent materials and procedures can 
delay or even prevent data and samples being used in research.17 For example, the cell 
lines reported by Conrad and colleagues in their 2008 paper, and expected to be 
available to researchers, had not been consented properly.18 Consent forms did not 
allow the cells to be retained after three years and they had to generate new ones, at 
the expense of time, funding and dissemination to the scientific community.19 As a 
Nature editorial notes about this case, “…the act of research and the ethics relating to 
a field of study are not always in synchrony, which can introduce unfortunate — and 
unacceptable — restrictions.”20 Such restrictions can block the progress of a member 
research study and seriously impact the work of the consortium. In order to try to 
avoid such inconsistencies, consent needs to be synchronised and harmonised, as far 
as possible, across consortium members. 
Examination of ICGC member consent materials 
In Spring 2010, the ICGC Ethics and Policy Committee (EPC) decided to examine 
how member projects had incorporated different core and suggested ICGC guideline 
elements21 into their consent materials. As well, the EPC was interested in knowing 
whether projects were using the ICGC Research Study Model Consent Brochure 
(Prospective Research) written by the EPC. (Supplemental data) Consent materials 
from ten projects, representing seven countries, were submitted to the EPC and 
reviewed. Materials from retrospective projects, having received an ethics committee 
waiver in order to participate, were not submitted and reviewed, as the original 
consents would not have mentioned ICGC. Only the language explaining scope of 
research, international data-sharing and return of individual research results was 
examined. This was due to the time and expense that would have been incurred to 
commission full and validated translations. Instead, where materials were in 
languages other than English, one of us (SW) translated the appropriate sections 
relating to these three topics. These translations were returned to a representative of 
the member project, who was asked to confirm that the translation was accurate. Four 
studies (from three countries) had used the model consent materials, designed to 
provide the keys points ICGC had decided needed to be included. These were new 
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studies specifically formed to participate in the ICGC. The other six projects had 
revised existing consent materials to meet the requirements of ICGC participation.  
 
We found that exact ICGC language was not used by every project. For example, as a 
core principle, consent materials must state that data and samples will be used for 
cancer research. However, as it is unclear where this research will lead in the future, 
the ICGC guidelines suggest that researchers be “…encouraged to seek the broadest 
level of consent that is appropriate at the local level; e.g., ‘cancer and related research; 
cancer and other disease-related research.’”22 All materials made it clear that the 
research was into cancer. But it was difficult to determine from the consent forms 
themselves exactly how far the consent extended beyond that point. This could be an 
issue when requests for data are received. Similarly, coded data from the member 
studies is put into open and controlled access databases that can be accessed by 
approved researchers around the world. Without consent for this, studies that do not 
ask for consent to such sharing cannot submit their data to the ICGC, thus negating 
the benefits of having that project as a member of the consortium. The review of the 
consent materials showed that that there might be ambiguities in the consents possibly 
hindering the sharing of the data when requests for access were received.  
 
In response, the ICGC Executive Committee decided to approach member projects to 
clarify that their datasets were consented in line with ICGC requirements on scope of 
research and international data-sharing or that they had obtained an acceptable ethics 
review committee waiver of consent. When joining ICGC, member studies were 
asked to agree to the ICGC policies, so adherence to other policy points was not 
reconfirmed. But it was decided that these two areas were sufficiently vital to the 
success of the ICGC that they should be confirmed independently. Unlike other 
consortia,23 the Executive chose not to require member projects to translate their 
consent forms in order to check compliance. Instead, the Executive asked for written 
clarification and confirmation on these two points from member studies with data 
ready for inclusion in ICGC databases as of Summer 2010 (Table 1). In this way, any 
potential ambiguities could be found and resolved, allowing data to be disseminated in 
accordance with ICGC policies and participants’ consent.  
 
Table 1: Questions to ICGC Project Leaders confirming the scope of research of their 
dataset and the ability to share that data internationally 
 
Scope of Research:  
1a. Is your dataset consented to be used for any approved biomedical 
research?   
Yes/No 
1b. Is your dataset consented to be used for cancer and related research 
(as opposed to only on one specific cancer type)?   
Yes/No 
International Data Sharing:  
2. Is your dataset consented to be shared with and used by ICGC and 
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At that time, seven studies had submitted data (available in the ICGC Open Access 
database; no controlled data was then available); this included both prospective 
studies whose consent materials we had reviewed and retrospective studies. All 
confirmed that their datasets were consented for any approved biomedical research (a 
broader scope of research than requested from studies) and international data-sharing. 
Member projects submitting data to the ICGC in the future will also be asked to 
confirm that their consent materials allow international data-sharing and to clarify the 
scope of permissible research. 
 
While admittedly covering only a limited number of studies, our research revealed 
potential problems and prompted action to deal with them. It also confirmed to us the 
importance of some of the processes undertaken by the ICGC when setting up the 
consortium, lessons that can be learned by other international consortia. First, it 
confirmed that international consortia need to determine core consent elements upon 
which all members agree and these need to be either in the consent materials or 
approved via an ethics committee waiver. Second, beyond the core elements, 
consortia need to have flexible guidelines in order to accommodate the differing 
ethical, legal and cultural norms of their members. Third, model consent language can 
help aid consistency across consents. Fourth, ambiguities and inconsistencies should 
be expected even with all of the above and action may need to be taken. Finally, 
governance procedures, such as examining ambiguities and resolving them, support 
the use of a broad consent for this type of research. Each of these will be discussed. 
Core consent elements are needed to form the backbone of the consortium 
Studies join a consortium to contribute their scientific efforts towards the common 
aim (e.g. the fight against cancer), as well as profit from collaborative research efforts 
provided by the members. In order to move these often disparate groups of 
researchers forward, agreement on the activities of the consortium is essential. In 
addition to requirements for quality standards for samples, analyses of genomic data 
and publication policies, the ICGC asks that projects agree to basic requirements, 
including core bioethical principles for prospective and retrospective research.24 
These principles reflect many of the basic tenets of research ethics (e.g. the right to 
withdraw, the right to decide without coercion, the right to have one's medical 
treatment not affected by a decision to not participate etc.). As well, they state 
information specific to this consortium that needs to be given to potential participants. 
As noted, such information includes international data sharing and the fact that data 
and samples will be used for cancer research. One ICGC-specific process is notifying 
potential participants that non-identifying elements of their data (e.g., cancer 
pathology or age range) will be placed in an open access database and that once 
placed there, it cannot be withdrawn as it will be impossible to know every instance of 
its use.25 Another specific process is that study researchers at the local level may 
conduct whole-genome sequencing on the samples they collect; this data is placed in 
the controlled access database. Whole-genome sequencing raises many ethical issues, 
such as feedback of individual results, privacy and future uses of the data,26 and 
participants should be informed of this research use.  
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Flexible guidelines allow different studies to work together 
Like a human backbone, the core elements give the consortium its stability. But a 
consortium, just like a human, needs to be able to move freely and adjust to 
circumstances. While the core principles set a minimum agreement for information 
that will be given to potential participants, flexible guidelines can help members to 
adhere to their own local requirements while conforming to ICGC structures. For 
example, one specific area in which ICGC has found a need for flexibility at the local 
level is the feedback of individual results.27 It was agreed that the ICGC would not 
take responsibility for returning individual genetic research findings discovered by 
those conducting downstream research. In common with other large scale genomic 
data and sample collection projects, this is a research project and is not involved with 
individual clinical care. Research findings are not expected to have individual 
predictive value; general research findings will be made available on the ICGC 
website.28 In addition, the data shared with the ICGC is coded; researchers accessing 
it agree not to re-identify individuals. However, the ICGC recognises that there may 
be an ethical, legal and/or medical imperative to return actionable findings of clinical 
significance to individuals and the most logical place for this responsibility is at the 
local level. Unlike ICGC, the investigators recruiting participants will have in place 
institutional mechanisms at their disposal to ensure proper processes are followed. 
Therefore the ICGC guidelines state that:  
 
Provided it is agreed at recruitment, if clinically important and 
validated findings emerge during the initial recruitment and 
screening phase, or in the early research, attempts will be made to 
pass this information back via the clinician, by whatever mechanism 
may be agreed at the local level.29 
 
However, the ICGC has recognised that this is a rapidly moving issue; the EPC is 
currently conducting research asking its members about their experiences with 
returning results and the particular issues that they faced. Findings will be published 
and used to craft future ICGC policy as well as to assist the international community 
on this issue. 
Model consent materials can aide consistency across member projects 
While the ICGC needs to allow flexibility in the wording of consent materials, it 
cannot be flexible with the core elements agreed to by the consortium, so model 
consent materials were created. Model consents are being used widely as they afford 
researchers guidance on items of information that should be included in materials in 
order to ensure compliance with requirements, consistency with their fellow 
consortium members, or to help them follow 'best practice.’30 The model consent for 
prospective research, based on the Public Population Project in Genomics (P3G) 
model templates,31 was designed for new ICGC studies and prospective studies 
revising their consent materials in light of ICGC participation. The ICGC Research 
Study Model Consent Brochure (Retrospective/Secondary Use of Research)32 aids 
projects seeking to re-consent participants in existing studies. Both provide model 
language for participating in a large-scale international consortium and can be 
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modified according to the cultural and regulatory requirements of the country or 
institution. Like other biospecimen-based projects, ICGC consent materials need to 
make clear how samples are being used and what data are being made available to the 
consortium and the wider research community. Participants need to be told how this 
will happen, how their identity will be protected, what information they can expect 
back from the project, what ongoing monitoring of regulatory compliances are in 
place as well as their rights and conditions of withdrawing from the project. What 
must be included is context-dependent;33 a consent form for research involving a 
patient facing surgery differs dramatically from one that a healthy volunteer signs to 
participate in a research biobank. However, when these activities begin to come 
together – participation in a biobank where one’s leftover tissue from oncological 
surgery will be used for future unknown research – it is important to be clear as to 
what information is necessary for informed consent.  
 
In addition, consent materials can vary greatly depending on the setting.34 The ICGC 
models help to remind researchers of the core elements that cannot be changed and 
need to be conveyed to potential participants and indicate where there is flexibility. 
For example, the model consent confirms the policy that once data is in the open 
access database, it cannot be withdrawn. But it also allows some flexibility regarding 
whether or not samples have to be destroyed or simply not used further:  
 
If you withdraw from the __[Study]__, your remaining samples [will 
be destroyed and], the data derived from any analyses done on your 
samples, and other personal information will be no longer used 
__[by the study]__.… Coded data placed in the Open-Access 
database cannot be withdrawn, but no additional information will be 
added.  
 
ICGC studies are not required to use the models, which were created as an aid and 
resource. While enforcement of the use of model consents might help achieve 
harmonised consent across the consortium, this process would no doubt involve the 
potential re-consent of hundreds of people, an effort most likely not budgeted for by 
many research studies. It would also potentially preclude the use of existing 
collections, which can be brought into ICGC with an ethics committee waiver. Re-
consent and making existing collections unusable would delay the work of the 
consortium and its goal of furthering cancer research and incur added expense. In 
preference, ICGC suggests using the models and recognises that consent materials 
will necessarily vary. Model consents can also help in other ways, such as with the 
ethics review process. One member has stated that it not only helped them with 
writing the consent materials, his IRB was also very appreciative, as it helped them to 
understand the aims and structure of the ICGC and the requirements of local 
participation.35 
Ambiguities and inconsistencies may still arise 
Even with model consents and guidance in place, the examination of the ICGC 
member consent materials showed that there are still ambiguities and inconsistencies 
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across the studies. This must be accepted; as noted earlier, international consortia such 
as ICGC have no top-down enforcement mechanisms available to them to impose 
requirements on members. Even when desired by a consortium, consent materials do 
not always conveniently use exact words. , Wording indicating breadth of consent, 
such as, for example, ‘for biomedical research’, is open to interpretation. Two causes 
for this can be pinpointed. First, the consent materials were a mix of new consents 
written using the wording of the ICGC model consent with existing consents adapted 
for ICGC use. This naturally introduced a lack of uniformity. The second issue is one 
that is faced my research studies that are part of a larger study creating ongoing 
resources for future research. For each member study, there is consent for the study 
itself, consent for consortium participation and consent for the future uses. These can 
get muddled with each other, as well as mixed with descriptions of the governance 
mechanisms being used to protect individuals at each stage. For example, following 
are examples of anonymised text from two of the prospective consents reviewed. In 
Table 2, this study asks for consent for cancer research. 
 
Table 2: Consent materials stating local ethics approval for participation in ICGC 
 
Consent Text Explanation/Interpretation 
“Your tissue will be stored in a freezer and will 
be used only by qualified Medical Researchers 
for biochemical and genetic studies of cancer. 
These studies aim to understand more about what 
causes [type of] cancer and why treatment seems 
to work for some…but not for others.”  
Initial research to which 
individual is consenting 
“We may also use your tissue to make long lived 
cell lines. Your tissue will be valuable for this 
research whether or not you have cancer.” 
Future research beyond the 
immediate study through the 
creation of cell lines 
“These studies have to be approved by the [title] 
Ethics Committees at the [Institution] and at the 
institution carrying out the research.” 
Ethics approval for future 
research both at site of initial 
research (i.e., to participate in 
ICGC) and other institutions (i.e., 
a researcher wishing to access 
data through ICGC) 
“These bodies abide by the ethical and scientific 
principles set out by the [recognised authority] of 
[country].” 
Use of national ethics and 
scientific principles to guide 
decision  
 
Participation in ICGC is included through the mechanism that the local institutional 
ethics committee will approve any future uses of the materials collected. This differs 
from the text in Table 3, which specifically states that samples and data will be used 
within the ICGC project. Future biomedical research is alluded to but not specifically 
stated. When asked, project leaders from both of these studies, as well as the others 
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Table 3: Consent materials including ICGC language 
 
Consent Text Explanation/Interpretation 
Cancer can result from changes in a person’s genetic 
material (DNA). By studying the genetic changes, 
researchers can learn what causes cancer. This will 
lead to new ways to prevent, detect and treat cancer…. 
Initial research 
Researchers will study the tumour cells grown…to 
learn about the genetic changes in the tumour. Some of 
these cells will also be stored for future research. 
Future research 
Scientists around the world are participating in the 
ICGC…. In [country], the [institution] is leading a 
study on the genetics of [type of] cancer.  
Participation in ICGC 
The ICGC was set up to help researchers investigate 
the genetic changes in cancer….The ICGC supports 
the sharing of data with the international research 
community. This may include researchers from 
academia, charitable organizations and the private 
sector, such as drug companies…. 
Core role of ICGC (cancer 
research) and description of 
international data sharing 
Researchers who use your data will sign agreements 
that define how your data may be used.… They must 
use it only for the purposes to which they agreed with 
the ICGC. 
Reliance on ICGC 
procedures for managing 
data access 
Appropriate governance mechanisms are needed to support the consent process 
Consents should aim to be as specific as possible, but not raise inappropriate barriers 
to research.  However, the protection of participants is paramount and the terms of 
their consents must be honoured. Ambiguous consents for future research are not 
ideal, but as shown by studies such as the UK Biobank, which successfully reached its 
target recruitment of 500,000 participants,36 people accept this wide ambit, asking in 
return to have appropriate governance committees and procedures in place to justify 
their trust.37 The ICGC has such mechanisms, such as the Executive Committee and 
the DACO, to oversee future research uses of participant data. If ambiguities and 
inconsistencies are suspected and confirmed, steps can be taken that might range from 
suggesting necessary adjustments that member projects can take, to considering 
possible sanctions for misuse of data.38 In this way, the ICGC will strive to satisfy 
both the aims of the consortium and the rights of participants.  
 
This confirmation process served several purposes for ICGC and may be applicable to 
other international consortia. On a practical level, it identified and allowed ICGC to 
clarify consent issues that might have limited access to ICGC data. In broader terms, 
it placed responsibility at the local member project level, rather than at the ICGC 
level, where local and national laws, regulations, ethics oversight and governance 
bodies can support study leaders and offer protection to participants. It also sent clear 
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policy messages to study leaders, member country governments and funders, and the 
scientific and lay community. The ICGC is committed to providing a resource for 
cancer research, and related research where possible, and disseminating it to approved 
researchers across the world, in accordance with the informed consent of its 
participants.  
Conclusion 
The requirement for informed consent is enshrined in bioethical codes of conduct, but 
how that consent process should be carried out and using what information will vary 
from study to study. In the case of the ICGC, the member studies represent differing 
ethico-legal and cultural environments and while this is respected, it is also recognised 
that without a harmonised process the work of the consortium will not proceed. 
Agreement on the activities of the consortium is essential, while acknowledging that 
the individual studies that are involved may represent different countries and cultures, 
as well as varying scientific methodologies. Clear principles, flexible guidelines and 
modifiable model language can help to ensure there is consistency and harmonisation 
of process. When potential ambiguities arise, a confirmation process can resolve 
differences.  
 
Some may say that this is not sufficient to protect those who agree to participate in 
international consortia studies. Perhaps other alternatives for oversight are possible, 
such as the creation of international bodies to which some governance powers could 
be delegated by national laws. But if or until such bodies exist, consortia members 
must work together at the international level to work towards harmonised practices 
across studies, while relying on national laws, regulatory systems and ethics norms at 
the local level. 
 
The ICGC is working hard to ensure that all data sets from member projects have the 
proper consents in place so that research will not be halted or delayed, and the trust of 
participants will be protected. The ICGC is confident its members will be able to work 
together towards the common goal of discovering and sharing vital knowledge in the 
fight against cancer, a goal supported enthusiastically by the participants who have 
made the research possible. We hope our experiences may benefit other international 
efforts as well. 
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